Literature DB >> 27779987

De novo Crohn's Disease after Ileal Pouch-Anal Anastomosis for Ulcerative Colitis and Inflammatory Bowel Disease Unclassified: Long-Term Follow-Up of a Prospective Inflammatory Bowel Disease Registry.

Karen Zaghiyan1, Jan P Kamiński, Galinos Barmparas, Phillip Fleshner.   

Abstract

The risk of de novo Crohn's disease (CD) after ileal pouch-anal anastomosis (IPAA) for ulcerative colitis (UC) versus inflammatory bowel disease unclassified (IBDU) or indeterminate colitis (IC) remains debatable. Here, we present updated results after long-term follow-up of a previously studied cohort of 334 patients with UC, IBDU, or IC who underwent IPAA during a 10-year period ending 2007. Of 334 study patients, 56 per cent were male and median age was 38 years (range: 8-81). Patients were classified as UC (n = 237) or IBDU (n = 97) preoperatively and UC (n = 236) or IC (n = 98) postoperatively. After a median follow-up of 76 months (range: 3-236), 63 patients (19%) developed CD within a median of 22 months (range: 1-213) from ileostomy closure compared with the previously published 40 patients (12%) with 26-month follow-up (P = 0.01). The development of de novo CD was similar for patients undergoing IPAA for UC (n = 40; 17%), IBDU (n = 21; 22%) or those classified as having UC (n = 42; 18%) or IC (n = 19; 19%) postoperatively; P > 0.05. Thus, patients with IBDU and IC can expect equivalent long-term outcome to patients with UC after IPAA. Pouch failure occurred in 13 (4%) study patients and was equal among all four groups.

Entities:  

Mesh:

Year:  2016        PMID: 27779987

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  8 in total

1.  The Incidence and Definition of Crohn's Disease of the Pouch: A Systematic Review and Meta-analysis.

Authors:  Edward L Barnes; Bharati Kochar; Hilary R Jessup; Hans H Herfarth
Journal:  Inflamm Bowel Dis       Date:  2019-08-20       Impact factor: 5.325

2.  Effective use of ustekinumab for prepouch ileitis without improvement of concomitant pouchitis.

Authors:  N Teich; A Stallmach
Journal:  Tech Coloproctol       Date:  2018-02-09       Impact factor: 3.781

Review 3.  Is There a Role for Ileal Pouch Anal Anastomosis in Crohn's Disease?

Authors:  Nicole E Lopez; Karen Zaghyian; Phillip Fleshner
Journal:  Clin Colon Rectal Surg       Date:  2019-06-17

4.  When Not to Pouch: Important Considerations for Patient Selection for Ileal Pouch-Anal Anastomosis.

Authors:  Shannon Chang; Bo Shen; Feza Remzi
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-08

5.  Inflammatory Pouch Conditions Are Common After Ileal Pouch Anal Anastomosis in Ulcerative Colitis Patients.

Authors:  Maia Kayal; Michael Plietz; Anam Rizvi; Marlana Radcliffe; Alexa Riggs; Clara Yzet; Emily Tixier; Parth Trivedi; Ryan C Ungaro; Sergey Khaitov; Patricia Sylla; Alexander Greenstein; Jean Frederic Colombel; Marla C Dubinsky
Journal:  Inflamm Bowel Dis       Date:  2020-06-18       Impact factor: 5.325

6.  Pre-pouch Ileitis is Associated with Development of Crohn's Disease-like Complications and Pouch Failure.

Authors:  Gaurav Syal; Ron Shemtov; Nirupama Bonthala; Eric A Vasiliauskas; Edward J Feldman; Karen Zaghiyan; Christina Y Ha; Dermot P B McGovern; Stephan R Targan; Gil Y Melmed; Phillip R Fleshner
Journal:  J Crohns Colitis       Date:  2021-06-22       Impact factor: 9.071

7.  Human alpha defensin 5 is a candidate biomarker to delineate inflammatory bowel disease.

Authors:  Amanda D Williams; Olga Y Korolkova; Amos M Sakwe; Timothy M Geiger; Samuel D James; Roberta L Muldoon; Alan J Herline; J Shawn Goodwin; Michael G Izban; Mary K Washington; Duane T Smoot; Billy R Ballard; Maria Gazouli; Amosy E M'Koma
Journal:  PLoS One       Date:  2017-08-17       Impact factor: 3.240

8.  Neoterminal Ileal Polyposis and Ulceration after Restorative Proctocolectomy with a Current Review of the Literature.

Authors:  Venkata Subhash Gorrepati; Negar Rassaei; Kofi Clarke
Journal:  Case Rep Gastroenterol       Date:  2018-04-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.